Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 3/20 | 0.38 |
| ▸ | CHRM5 | P08912 | 2/20 | 0.38 |
| ▸ | CHRM3 | P20309 | 2/20 | 0.38 |
| ▸ | ABCC1 | P33527 | 1/20 | 0.35 |
| ▸ | KHK | P50053 | 1/20 | 0.32 |
| ▸ | JAK3 | P52333 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | NPFFR1 | Q9GZQ6 | 1/20 | 0.31 |
| ▸ | NPFFR2 | Q9Y5X5 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16119427 | 1.00 | SIGMAR1 (0.38) | SIGMAR1CHRM5CHRM3ABCC1KHK | |
| SCHEMBL17457735 | 0.96 | CHRM5 (0.38) | SIGMAR1CHRM5CHRM3ABCC1KDM4E | |
| SCHEMBL17465733 | 0.96 | CHRM5 (0.38) | SIGMAR1CHRM5CHRM3ABCC1KDM4E | |
| SCHEMBL17457715 | 0.90 | SMYD3 (0.39) | ABCC1KHKKDM4EALDH1A1 | |
| SCHEMBL16119468 | 0.90 | SMYD3 (0.39) | ABCC1KHKKDM4EALDH1A1 | |
| SCHEMBL17465753 | 0.90 | ALDH1A1 (0.34) | KDM4EALDH1A1MAPT | |
| SCHEMBL16100502 | 0.90 | ALDH1A1 (0.34) | KDM4EALDH1A1MAPT | |
| SCHEMBL17465696 | 0.88 | ALDH1A1 (0.35) | KDM4EALDH1A1MAPT | |
| SCHEMBL16100710 | 0.88 | ALDH1A1 (0.35) | KDM4EALDH1A1MAPT | |
| SCHEMBL21698365 | 0.88 | ABCC1 (0.32) | SIGMAR1CHRM5CHRM3ABCC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2970340-B1 | BETA-LACTAMASE INHIBITORS | VENATORX PHARMACEUTICALS INC (US) | 2020-02-12 | — | — | EP | disclosed |
| US-10294248-B2 | Beta-lactamase inhibitors | VenatoRx Pharmaceuticals, Inc. (US) | 2019-05-21 | — | — | US | disclosed |
| US-20180273552-A1 | BETA-LACTAMASE INHIBITORS | NATIONAL INSTITUTES OF HEALTH | 2018-09-27 | — | — | US | disclosed |
| US-9944658-B2 | Beta-lactamase inhibitors | VenatoRx Pharmaceuticals, Inc. (US) | 2018-04-17 | — | — | US | disclosed |
| US-20160024121-A1 | BETA-LACTAMASE INHIBITORS | VenatoRx Pharmaceuticals, Inc. | 2016-01-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180273552-A1 | BETA-LACTAMASE INHIBITORS | MGAM, GAA, LCT | SIGMAR1 3058/4885CHRM5 4213/4885CHRM3 4549/4885 |
| US-10294248-B2 | Beta-lactamase inhibitors | MGAM, GAA, LCT | SIGMAR1 3058/4885CHRM5 4213/4885CHRM3 4549/4885 |
| US-20160024121-A1 | BETA-LACTAMASE INHIBITORS | MGAM, GAA, LCT | SIGMAR1 3058/4885CHRM5 4213/4885CHRM3 4549/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.